Literature DB >> 27908528

Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.

Dimitrios Nasioudis1, Eloise Chapman-Davis2, Steven S Witkin2, Kevin Holcomb2.   

Abstract

OBJECTIVE: The aim of the present study was to investigate the prevalence of lymph node (LN) metastasis in women with apparent stage I ovarian carcinoma of endometrioid or mucinous histology and to examine the prognostic significance of LN sampling/dissection (LND) on patient survival.
METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was accessed and a cohort of surgically-staged women, diagnosed between 1988 and 2013, with apparent stage I ovarian carcinoma of mucinous or endometrioid histology was selected. Information derived from the histopathology report was employed to determine whether LND was performed and the status of harvested LNs. Five-year cancer-specific survival (CSS) rate was calculated following generation of Kaplan-Meier curves. Comparisons were made using the log-rank test. Cox proportional hazard models were constructed to evaluate the effect of LND on survival.
RESULTS: A total of 3354 and 2855 women with endometrioid and mucinous tumors who met the inclusion criteria were identified. LND was performed in 2307 (68.8%) and 1602 (56.1%) of them (p<0.001), respectively. The rate of histopathologically confirmed LN metastasis was 2.1% and 1.7%, respectively. By multivariate analysis LND was associated with superior cancer-specific mortality only for women with endometrioid carcinoma.
CONCLUSIONS: Lymph node involvement in women with mucinous and endometrioid ovarian carcinoma grossly confined to the ovary is infrequent. LND is associated with a survival advantage for those with endometrioid carcinoma.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymphadenectomy; Mucinous adenocarcinoma; Ovarian neoplasms; Ovary; Serous adenocarcinoma

Mesh:

Year:  2016        PMID: 27908528     DOI: 10.1016/j.ygyno.2016.11.038

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma.

Authors:  Wei Lin; Dongyan Cao; Xiaohua Shi; Yan You; Jiaxin Yang; Keng Shen
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas.

Authors:  Hiroaki Soyama; Morikazu Miyamoto; Masashi Takano; Hideki Iwahashi; Kento Kato; Takahiro Sakamoto; Mika Kuwahara; Hiroki Ishibashi; Hiroko Matuura; Tomoyuki Yoshikawa; Tadashi Aoyama; Hitoshi Tsuda; Kenichi Furuya
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

3.  Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma.

Authors:  Yu Zhao; Shu Wang; Yi-Min Qu; Yu-Ting Ji; Keng Shen; Jing He Lang
Journal:  J Ovarian Res       Date:  2017-09-18       Impact factor: 4.234

4.  Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?

Authors:  Dimitrios Nasioudis; Eloise Chapman-Davis; Melissa K Frey; Steven S Witkin; Kevin Holcomb
Journal:  J Gynecol Oncol       Date:  2017-07-03       Impact factor: 4.401

5.  Borderline tumours of the ovary: Common practice in the Netherlands.

Authors:  Koen De Decker; Henk G Ter Brugge; Joost Bart; Roy F P M Kruitwagen; Hans W Nijman; Arnold-Jan Kruse
Journal:  Gynecol Oncol Rep       Date:  2018-12-10

6.  Frozen section diagnosis of borderline ovarian tumors with suspicious features of invasive cancer is a devil's dilemma for the surgeon: A systematic review and meta-analysis.

Authors:  Koen De Decker; Karina H Jaroch; Mireille A Edens; Joost Bart; Loes F S Kooreman; Roy F P M Kruitwagen; Hans W Nijman; Arnold-Jan Kruse
Journal:  Acta Obstet Gynecol Scand       Date:  2021-02-22       Impact factor: 4.544

7.  An Application of Machine Learning That Uses the Magnetic Resonance Imaging Metric, Mean Apparent Diffusion Coefficient, to Differentiate between the Histological Types of Ovarian Cancer.

Authors:  Heekyoung Song; Seongeun Bak; Imhyeon Kim; Jae Yeon Woo; Eui Jin Cho; Youn Jin Choi; Sung Eun Rha; Shin Ah Oh; Seo Yeon Youn; Sung Jong Lee
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

8.  Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study.

Authors:  Koen De Decker; Karina H Jaroch; Joost Bart; Loes F S Kooreman; Roy F P M Kruitwagen; Hans W Nijman; Arnold-Jan Kruse
Journal:  J Ovarian Res       Date:  2021-10-22       Impact factor: 4.234

9.  Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study.

Authors:  Yoshiki Ikeda; Masato Yoshihara; Satoshi Tamauchi; Akira Yokoi; Nobuhisa Yoshikawa; Hiroaki Kajiyama
Journal:  J Gynecol Oncol       Date:  2022-02-21       Impact factor: 4.756

10.  Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma.

Authors:  Tong Ren; Shu Wang; Jian Sun; Ji-Min Qu; Yang Xiang; Keng Shen; Jing He Lang
Journal:  J Ovarian Res       Date:  2017-10-03       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.